Artikel von Andreas Zehetner
Andreas Zehetner has been intensively engaged in various trading strategies since 2015 and is himself a passionate trend-following trader. In webinars and short video coaching sessions, he regularly presents different analysis methods. Focusing on the US market, Andreas identifies interesting breakout opportunities in leading growth stocks as part of the NEO-DARVAS strategy and based on the frameworks of legends like William O’Neil or Mark Minervini.Latest from Andreas Zehetner
United Therapeutics wins important patent dispute – Yutrepia under pressure with PH-ILD
United Therapeutics wins an important patent dispute against Liquidia. Yutrepia could lose its PH-ILD...
Synopsys Raises Long-Term Goals – New Royalties, Amazon Deal, and GPT-Synopsys Drive Growth
Synopsys expects an annual revenue growth of around 15% by 2030. EPS and free cash flow are projected...
Howmet Aerospace: Buying opportunity despite SpaceX and GE concerns? Citi sees over 40% potential
Citi places Howmet Aerospace on the "Upside 90-Day Catalyst Watch” and reaffirms its buy rating with...
Marvell: The Most Exciting Indirect Beneficiary of Anthropic's $518 Billion AI Offensive
Marvell Technology (MRVL) is seen as a particularly exciting indirect beneficiary of Anthropic's infrastructure...
IDT Corporation: From Telecom Company to Fintech and AI Platform – Stock Reaches All-Time High
IDT is transforming from a traditional telecom company into a platform for fintech, point-of-sale systems,...
AMD Accelerates AI Offensive: Helios, Anthropic, and $8.2 Billion Acquisition
AMD wins billion-dollar AI contracts with OpenAI, Meta, and Anthropic, expanding Helios as an alternative...
Tesla secures $30 billion – AI, proprietary chips, and robotaxis drive investment offensive
Tesla secures credit lines of $30 billion, providing additional financial flexibility for an exceptionally...
IQVIA: Record Drug Approvals Highlight Growing Importance in the Age of AI
For me, the strategic significance of IQVIA Holdings (IQV, i) is clearly increasing in the age of AI....
AbbVie: Back on Growth Path After Humira – New Billion-Dollar Potentials and P/E 16.4
AbbVie is a leading biopharmaceutical company and is increasingly offsetting the decline of Humira...
Xometry Gains Market Share as an AI Marketplace for the Manufacturing World
About 5,000 active manufacturing partners in 50 countries form a scalable production network. Xometry...
AstraZeneca bets on Ivonescimab: Summit Therapeutics rises 18% in after-hours trading
AstraZeneca invests $2 billion in Summit Therapeutics, causing the stock to rise approximately 18%...
Anthropic: $518 billion for AI infrastructure – new Claude model accelerates the offensive
Anthropic increased revenue to $4.6 billion in 2025, bringing it to twelve times that of the previous...
Amprius Technologies: New U.S. Funding Strengthens the Comeback Story
After the pullback of around 54% from its all-time high, I see an interesting speculative entry opportunity...
NVIDIA: New platform secures AI agents – Stock buyback rises to 235 billion USD
NVIDIA launches a security platform for AI agents. OpenShell limits access, while Sentry can stop agents...
PC Connection: Order Backlog at Record Level – AI and PC Refresh as Drivers
PC Connection benefits from the ongoing PC refresh cycle and increasing investments in AI-capable infrastructure,...
Waters: New Growth Cycle in Laboratory Instruments Meets AI Biotechnology
Waters benefits from the broader recovery in instruments. Organic growth is back in the high single-digit...
TSMC: 2-nm Demand Accelerates – Nvidia, Apple & Co. Increase Capacities
Apple, Nvidia, AMD, Qualcomm, and MediaTek have reportedly increased their reserved 2-nm capacities...
Rubrik: AI Agents Drive the Cyber Resilience Story – For Me, it is a New Top Pick
The recent warnings from Anthropic highlight how quickly autonomous AI agents can become a new security...
Matson: Strong Demand from Asia and High Freight Rates - Stock at a Record High
Matson transports container freight and combines Jones Act-protected US Pacific services with especially...
Iovance Biotherapeutics: Amtagvi Grows by 68% – Lung Cancer Opens Seven Times Larger Market Opportunity
Iovance is developing TIL cell therapies for solid tumors and already markets an approved therapy...